Medtech MedSurg and Neurotechnology operating margin measures segment operating income as a percentage of segment net sales.
Stryker reported a 28.1% MedSurg and Neurotechnology operating margin in the second quarter of 2026, up from 25.6% a year earlier.
Volume and operating expenses improved conversion
Stryker's margin bridge showed positive contributions from volume, manufacturing and supply-chain costs, and lower SG&A intensity, partly offset by R&D expense.
The measure therefore captures profit conversion rather than product-family demand alone.
Segment margin preserves Stryker's cost allocation
The margin follows Stryker's reportable-segment accounting and should not be treated as a standardized medtech peer margin.
Read it with Instruments constant-currency sales growth and Medical constant-currency sales growth.
Primary source: Stryker Q2 2026 Form 10-Q.
Part of the Medtech Product Family Economics
See It in Company Research
These companies are examples of how the concept is reported or discussed in public filings. Definitions can differ by issuer; these links open company research rather than a normalized metric comparison.
- SYKOpen operating-model research →10 of 10 reviewed concepts in Medtech Product Family EconomicsSegment operating conversion2 of 2 bridge concepts supportedContinue through this bridge:Orthopaedics Operating Margin
Continue Research
Continue from the concept into the Grizzly Bulls research surface that best matches the next question. These links are research continuations, not recommendations or required steps.
Compare MedSurg and Neurotechnology margins
Compare segment operating conversion with volume, supply-chain costs, R&D, SG&A, and issuer cost allocation preserved.
Explore more topics in the Financial Research Encyclopedia.